Optimi Health draws focus as FDA advances psychedelic-drug review
AI Summary- Optimi Health manufactures and exports MDMA and psilocybin for authorized medical programs.
- $28.057 million market cap accompanied a 0.61% overnight gain in OPTH shares.
- FDA held a Sept. 14, 2026, hearing on potential future therapeutic psychedelic use.